These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
723 related items for PubMed ID: 12183723
1. Idiopathic thrombocytopenic purpura diagnosed during the second decade of life. Lowe EJ, Buchanan GR. J Pediatr; 2002 Aug; 141(2):253-8. PubMed ID: 12183723 [Abstract] [Full Text] [Related]
2. Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama. Watts RG. Clin Pediatr (Phila); 2004 Oct; 43(8):691-702. PubMed ID: 15494875 [Abstract] [Full Text] [Related]
4. Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy. Pamuk GE, Pamuk ON, Başlar Z, Ongören S, Soysal T, Ferhanoğlu B, Aydin Y, Ulkü B, Aktuğlu G, Akman N. Ann Hematol; 2002 Aug; 81(8):436-40. PubMed ID: 12224000 [Abstract] [Full Text] [Related]
6. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Schwartz J, Leber MD, Gillis S, Giunta A, Eldor A, Bussel JB. Am J Hematol; 2003 Feb; 72(2):94-8. PubMed ID: 12555211 [Abstract] [Full Text] [Related]
8. Twenty years experience with treatment of idiopathic thrombocytopenic purpura in a single department: results in 490 cases. Schiavotto C, Rodeghiero F. Haematologica; 1993 Feb; 78(6 Suppl 2):22-8. PubMed ID: 8039754 [Abstract] [Full Text] [Related]
10. Efficacy, safety, and dose response of intravenous anti-D immune globulin (WinRho SDF) for the treatment of idiopathic thrombocytopenic purpura in children. Freiberg A, Mauger D. Semin Hematol; 1998 Jan; 35(1 Suppl 1):23-7. PubMed ID: 9523746 [Abstract] [Full Text] [Related]
11. Management of adult idiopathic thrombocytopenic purpura. Nakhoul IN, Kozuch P, Varma M. Clin Adv Hematol Oncol; 2006 Feb; 4(2):136-44, 153. PubMed ID: 16728922 [Abstract] [Full Text] [Related]
12. Clinical experience with anti-D in the treatment of idiopathic thrombocytopenic purpura. Scaradavou A, Bussel JB. Semin Hematol; 1998 Jan; 35(1 Suppl 1):52-7. PubMed ID: 9523749 [Abstract] [Full Text] [Related]
13. Outcome of chronic idiopathic thrombocytopenic purpura in children. Bansal D, Bhamare TA, Trehan A, Ahluwalia J, Varma N, Marwaha RK. Pediatr Blood Cancer; 2010 Mar; 54(3):403-7. PubMed ID: 19908301 [Abstract] [Full Text] [Related]
14. Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura. Kumar M, Vik TA, Johnson CS, Southwood ME, Croop JM. Am J Hematol; 2005 Mar; 78(3):181-7. PubMed ID: 15726607 [Abstract] [Full Text] [Related]
15. A population-based, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children. Glanz J, France E, Xu S, Hayes T, Hambidge S. Pediatrics; 2008 Mar; 121(3):e506-12. PubMed ID: 18310170 [Abstract] [Full Text] [Related]
17. Experience with high dose dexamethasone in the treatment of chronic symptomatic immune thrombocytopaenia. Van Riet FA, Wessels G, Hesseling PB. East Afr Med J; 1999 Oct; 76(10):571-4. PubMed ID: 10734508 [Abstract] [Full Text] [Related]
19. A follow-up study of 49 adult patients with idiopathic thrombocytopenic purpura treated with high-dose immunoglobulins and anti-D immunoglobulins. Rodeghiero F, Schiavotto C, Castaman G, Vespignani M, Ruggeri M, Dini E. Haematologica; 1992 Jan; 77(3):248-52. PubMed ID: 1330848 [Abstract] [Full Text] [Related]